Pairwise RMSD comparison of seven protein structures binding imatinib, a small molecule tyrosine kinase inhibitor for cancer treatment, is able to separate tyrosine kinases (on-targets) from quinone reductase (reported off-target [55]), see Fig. 1.T10. Here, NQO1 is linked to cancer.